Filing search / Incannex Healthcare Limited / "Strategy"

PRE 14A

IXHL Incannex Healthcare Limited

31 Oct 24

Preliminary proxy

4:10pm

International, bringing extensive expertise in corporate strategy and global market expansion. The board of directors has concluded that Mr. Latham … should serve as a director because of his extensive leadership, business and corporate strategy expertise in the life sciences industry. Troy Valentine

8-K

EX-99.1

IXHL Incannex Healthcare Limited

24 Oct 24

Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

7:30am

development, regulatory strategy, and global medical affairs, Dr. Barbato brings significant drug development expertise in psychiatric and neurological … disorder, and rheumatoid arthritis,” said Dr. Barbato. “I look forward to leading our global clinical strategy for IHL-42X, PSX-001 and IHL-675A

8-K

EX-10.1

IXHL Incannex Healthcare Limited

15 Oct 24

Entry into a Material Definitive Agreement

3:54pm

), each Obligor must meet with the Financier promptly and all parties must consult in good faith with a view to agreeing a strategy to rectify

8-K

EX-99.1

IXHL Incannex Healthcare Limited

30 Sep 24

Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates

4:01pm

include statements about, among other things: Incannex’s business strategy, future operations; Incannex’s ability to execute on its objectives, prospects

10-K

2024 FY

IXHL Incannex Healthcare Limited

30 Sep 24

Annual report

7:30am

of operations, financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases … events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking

8-K

EX-99.1

1hsz8v5mip9t320w

5 Aug 24

FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed

8:15am

8-K

EX-99.1

4g18scp4gnpo

30 Jul 24

Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X

9:00am

S-1/A

df3az9h16p

17 Jul 24

IPO registration (amended)

8:47am

S-1

g2ol37ky

3 Jul 24

IPO registration

6:29am

8-K

EX-99.1

i4vpcy8dxoslyna0mv1v

30 May 24

Other Events

8:30am

8-K

EX-99.1

gxy mc2az

7 May 24

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder

8:30am

8-K

EX-99.1

9lsjl

16 Apr 24

Incannex Healthcare Inc. Quarterly Update, Q1 2024

9:30am

8-K

EX-99.1

k6zuyq8z0u4wa9z

28 Feb 24

Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder

7:42am

8-K

EX-99.1

mnoes fjaszd6vg04tb1

16 Feb 24

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation

8:00am

10-Q

p99im8 5q

14 Feb 24

Quarterly report

6:16am

8-K

EX-99.1

za0 homm0

1 Feb 24

Other Events

7:30am

8-K

EX-99.1

gcssmmbx59

24 Jan 24

Other Events

4:30pm

8-K

EX-99.1

st73b9usqp mm

18 Jan 24

Other Events

9:08am

8-K

EX-99.1

xqa0hti8siist

17 Jan 24

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

6:05am